Location of CD39+ T cell subpopulations within tumors predict differential outcomes in non-small cell lung cancer

被引:11
作者
Koppensteiner, Lilian [1 ]
Mathieson, Layla [1 ]
Pattle, Samuel [2 ]
Dorward, David A. [2 ]
O'Connor, Richard [1 ]
Akram, Ahsan R. [1 ,3 ]
机构
[1] Univ Edinburgh, Ctr Inflammat Res, Edinburgh, Scotland
[2] Royal Infirm, Dept Pathol, Edinburgh, Scotland
[3] Univ Edinburgh, Inst Genet & Mol Med, Canc Res UK Edinburgh Ctr, Edinburgh, Scotland
关键词
tumor biomarkers; biomarkers; tumor; immune checkpoint inhibitors; lung neoplasms; non-small cell lung cancer; TERTIARY LYMPHOID STRUCTURES; STROMAL CELLS; RESPONSES;
D O I
10.1136/jitc-2023-006770
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose An improved mechanistic understanding of immunosuppressive pathways in non-small cell lung cancer (NSCLC) is important to develop novel diagnostic and therapeutic approaches. Here, we investigate the prognostic significance of the ectonucleotidases CD39 and CD73 in NSCLC.Experimental design The expression and localization of CD39, CD73 and CD103 was digitally quantified in a cohort of 162 early treatment naive NSCLC patients using multiplex-immunofluorescence and related to patient outcome. Expression among different cell-populations was assessed via flow cytometry. Targeted RNA-Seq was performed on CD4(+) and CD8(+) T cells from digested NSCLC tumor tissue and single-cell RNA-Seq data was analyzed to investigate the functional significance of CD39(+) T cell populations.Results We demonstrate that flow cytometry of early untreated NSCLC patients shows an upregulation of CD39 expression in the tumor tissue among natural killer (NK) cells, fibroblasts and T cells. CD73 expression is mainly found among fibroblasts and Epcam+cells in the tumor tissue. Multiplex Immunofluorescence in a cohort of 162 early untreated NSCLC patients demonstrates that CD39 expression is mainly localized in the tumor stroma while CD73 expression is equally distributed between tumor nest and stroma, and high expression of CD39 and CD73 in the tumor stroma is associated with poor recurrence-free survival (RFS) at 5 years. Additionally, we find that CD8+T cells located in the tumor nest express CD103 and the density of CD39+CD103+CD8+ T cells in the tumor nest predicts improved RFS at 5 years. Targeted RNA-Seq shows that the tumor microenvironment of NSCLC upregulates regulatory pathways in CD4+ T cells and exhaustion in CD8(+) T cells, and analysis of a single cell RNA sequencing dataset shows that CD39(+)CD4(+) cells are enriched in Treg signature gene-sets, and CD39(+)CD103(+)cytotoxic T lymphocyte show gene signatures indicative of an exhausted cytotoxic phenotype with upregulated expression of CXCL13.Conclusions Knowledge of patterns of distribution and location are required to understand the prognostic impact of CD39(+) T cell populations in NSCLC. This study provides an improved understanding of spatial and functional characteristics of CD39(+) T cells and their significance to patient outcome.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Prognostic value of CD4+ T lymphopenia in non-small cell lung Cancer
    Guillaume Eberst
    Dewi Vernerey
    Caroline Laheurte
    Aurélia Meurisse
    Vincent Kaulek
    Laurie Cuche
    Pascale Jacoulet
    Hamadi Almotlak
    Jean Lahourcade
    Marie Gainet-Brun
    Elizabeth Fabre
    Françoise Le Pimpec-Barthes
    Olivier Adotevi
    Virginie Westeel
    BMC Cancer, 22
  • [22] Dynamics of peripheral T cell clones during PD-1 blockade in non-small cell lung cancer
    Zhang, Fan
    Bai, Hua
    Gao, Ranran
    Fei, Kailun
    Duan, Jianchun
    Zhang, Zemin
    Wang, Jie
    Hu, Xueda
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2020, 69 (12) : 2599 - 2611
  • [23] Multi-omics and artificial intelligence predict clinical outcomes of immunotherapy in non-small cell lung cancer patients
    Mei, Ting
    Wang, Ting
    Zhou, Qinghua
    CLINICAL AND EXPERIMENTAL MEDICINE, 2024, 24 (01)
  • [24] Biomarkers of immunotherapy for non-small cell lung cancer
    Shirasawa, Masayuki
    Yoshida, Tatsuya
    Ohe, Yuichiro
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 54 (01) : 13 - 22
  • [25] Principles of Immunotherapy in Non-Small Cell Lung Cancer
    Hsu, Melinda L.
    Naidoo, Jarushka
    THORACIC SURGERY CLINICS, 2020, 30 (02) : 187 - +
  • [26] Surveillance of resected non-small cell lung cancer
    Lopez-Gonzalez, A.
    Ibeas Millan, P.
    Cantos, B.
    Provencio, M.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2012, 14 (10) : 721 - 725
  • [27] T cell immunity in interstitial lung disease with non-small cell lung cancer patients
    Isono, Tomomi
    Iwahori, Kota
    Yanagawa, Masahiro
    Yamamoto, Yoko
    Tone, Mari
    Haruna, Miya
    Hirata, Michinari
    Fukui, Eriko
    Kimura, Toru
    Kanou, Takashi
    Ose, Naoko
    Funaki, Soichiro
    Takeda, Yoshito
    Morii, Eiichi
    Kumanogoh, Atsushi
    Shintani, Yasushi
    Wada, Hisashi
    LUNG CANCER, 2023, 182
  • [28] Metabolomics and lipidomics in non-small cell lung cancer
    Shi, Wei
    Cheng, Yizhen
    Zhu, Haihua
    Zhao, Longshan
    CLINICA CHIMICA ACTA, 2024, 555
  • [29] Non-small cell lung cancer – ASCO 2009
    Sacha Rothschild
    O. Gautschi
    memo - Magazine of European Medical Oncology, 2009, 2 (4) : 202 - 205
  • [30] Non-small cell lung cancer - ASCO 2009
    Rothschild, S.
    Gautschi, O.
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2009, 2 (04) : 202 - 205